Rana McKay, MD
Rana McKay, MD, is a medical oncologist at the University of California, San Diego Moores Cancer Center.
Articles by Rana McKay, MD
The panel shares insights on future advancements in the field.
The panel discussed the "innovative design" of the phase 2 ENZA-p study presented at ESMO 2023.
The panel discusses treatment-related adverse events, including hematologic toxicities, xerostomia, and more.
The panel discuss patient interest in receiving radioligand therapy in the context of cost and access challenges.
The panel discusses results of the phase 3 PSMAfore study presented at ESMO 2023.
The panel talks "pearls of wisdom" with radioligand therapy.
The panel discusses recommended frequency of scans for patients receiving radioligand therapy, PSA response, and more.
The panel discussed initial access issues with radioligand therapy, as well as interdisciplinary team collaboration.
Dr. McKay discusses upcoming prostate cancer data to be presented at ESMO and discussed at The Uromigos: Live & Unplugged.
Drs. Lee and McKay discuss the latest data on KEYNOTE-B61 for first-line lenvatinib plus pembrolizumab for nccRCC.
Drs. McKay and Braun wrap up their discussion with comments on which novel therapies hold the most promise in advanced RCC.
Drs. McKay and Braun share their strategy for strategy for patient selection in the clinic, including first- and second-line.
Drs. McKay and Braun highlights novel RCC biomarkers being developed, including imaging-, pathology-, and blood-based ones.
Dr. McKay speaks with Dr. Braun on the current biomarker landscape for RCC and how biomarkers have shaped treatment.
Dr Rana McKay shares how the approval of enfortumab vedotin plus pembrolizumab impacts patients with advanced UC.
Dr. McKay explains how radiation therapy and modalities fit into the treatment paradigm for RCC.
Dr. McKay summarizes the novel therapies or optimal sequencing patterns that are close to entering the mRCC treatment space.
Dr. McKay offers an overview of the second-line and later-line therapy options after progression for metastatic RCC.
Dr. McKay highlights the results of a few studies that support the use of frontline immunotherapy for favorable-risk mRCC.
Dr. Rana McKay details how advanced or mRCC is currently managed and how the treatment paradigm has evolved since 2018.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.